logo
Menu
Innovation Observatory > Reports > Drugs > Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line

< Back

Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line

Drugs

Cancer and Palliative Care

November 2017


Lenalidomide in combination with bortezomib and dexamethasone is being developed for the treatment of adult patients with MM. While each of these drugs are already approved for treating a range of malignant blood diseases, the combination of the three drugs has shown significant potential particularly for the treatment of newly diagnosed MM. If approved, it will offer an additional treatment option for adult patients whether or not they are eligible or ineligible for bone marrow transplant.

 

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Lenalidomide for Multiple Myeloma



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts
Get Alerts